rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LGND
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stifel raises Ligand Pharma stock price target on strong earnings
      Oct 29Investing.comLGND
      Ligand Pharma (LGND) Receives a Buy from Bank of America Securities

      Tipranks Press Release.

      Oct 20The Globe and MailLGND
      Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock
      Oct 11Investing.comLGND
      This Pharma Giant Has The Right Medicine For Income Investors

      Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb.

      Sep 30Investor's Business DailyLGNDBMY
      SpaceX Wins Analyst Praise, Buy Ratings After Starship Flight 14

      Wall Street analysts react to the outcome of SpaceX's Starship flight 14 mission on Monday, eye potential for future launches.

      Sep 29Investor's Business DailyLGNDSPCX
      Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?

      Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...

      Sep 29Yahoo FinanceLGND
      Nasdaq, S&P 500 Hold Firm Ahead Of Inflation Report: SharkNinja, Advantest, ASE Technology In Focus - Video - IBD
      Sep 28Investor's Business DailyLGNDMRXCNQEROEW
      Choppy Market Persists; Palo Alto Networks, Ligand Pharma, NetApp Lead - Video - IBD
      Sep 28Investor's Business DailyLGND
      Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation (LGND:NASDAQ)
      Sep 25Seeking AlphaLGNDBCS
      Barclays initiates Ligand Pharma stock with overweight rating
      Sep 25Investing.comLGND
      Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal
      Sep 24Investing.comLGND
      Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Mediwound (MDWD)

      Detailed price information for Ligand Pharm (LGND-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailLGNDMDWD
      Ligand Pharma Expands Ophthalmology Royalties With Ryjunea Deal

      Detailed price information for Ligand Pharm (LGND-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailLGND
      Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold
      Sep 19Seeking AlphaLGND
      Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech (NASDAQ:LGND)
      Sep 18Seeking AlphaLGND

      This is the newest page. Registered accounts read further back.